<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCT</journal-id><journal-title-group><journal-title>Journal of Cancer Therapy</journal-title></journal-title-group><issn pub-type="epub">2151-1934</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jct.2018.91001</article-id><article-id pub-id-type="publisher-id">JCT-81591</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Radiation Therapy Prophylaxis for Heterotopic Ossification in Non-Hip Sites
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ajaykumar</surname><given-names>B. Patel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Katherine</surname><given-names>S. Tzou</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Megan</surname><given-names>Single</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Laeticia</surname><given-names>Hollant</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bridget</surname><given-names>Smart</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Katherine</surname><given-names>Gaines</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Courtney</surname><given-names>E. Sherman</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jennifer</surname><given-names>L. Peterson</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Stephen</surname><given-names>J. Ko</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Laura</surname><given-names>A. Vallow</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Robert</surname><given-names>C. Miller</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Steven</surname><given-names>J. Buskirk</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Northside Radiation Oncology Consultants, Atlanta, GA, USA</addr-line></aff><aff id="aff2"><addr-line>Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA</addr-line></aff><aff id="aff4"><addr-line>University of Central Florida, Orlando, FL, USA</addr-line></aff><aff id="aff5"><addr-line>University of Florida, Gainesville, FL, USA</addr-line></aff><aff id="aff7"><addr-line>Department of Orthopedic Surgery, Mayo Clinic, Jacksonville, FL, USA</addr-line></aff><aff id="aff3"><addr-line>College of Medicine, University of Kentucky, Lexington, KY, USA</addr-line></aff><aff id="aff6"><addr-line>University of North Florida, Jacksonville, FL, USA</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>ajaykumarbpatel@gmail.com(ABP)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>01</month><year>2018</year></pub-date><volume>09</volume><issue>01</issue><fpage>1</fpage><lpage>8</lpage><history><date date-type="received"><day>14,</day>	<month>November</month>	<year>2017</year></date><date date-type="rev-recd"><day>2,</day>	<month>January</month>	<year>2018</year>	</date><date date-type="accepted"><day>5,</day>	<month>January</month>	<year>2018</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background
  : 
  Radiation therapy prophylaxis for heterotopic ossification is well-established for the hip, either pre or post-operatively. There is limited data for this treatment in non-hip sites. We report our institution’s experience. <b>Methods</b>
  <b>: </b>
  From October 2004 to August 2015, a total of 39 non-hip sites in 38 patients were treated with prophylactic radiation therapy for heterotopic ossification at our institution. An IRB approved retrospective review was performed. There were 15 patients who received treatments to the elbow, 13 to the knee (1 bilateral for a total of 14 knees), and 10 to other sites (leg stump (2), pubic symphysis (2), femur (1), foot (1), humerus stump (1), abdominal wall (1), shoulder (1), thigh (1)). All but 1 patient were treated with a single fraction treatment with 700 or 800 cGy.
   
  One patient received 2000 cGy in 10 fractions to the abdominal wall for heterotopic ossification extending from the xiphoid process. <b>Results</b>
  <b>:</b>
   
  Fifteen patients underwent treatment to the elbow with a median follow-up of 5 months (0
   
  -
   
  99). Median age for this group was 50 years (37
   
  -
   
  69). Nine (60.0%) patients had evidence of heterotopic ossification prior to surgery. All (100%) of the elbow patients were free from recurrence at last follow-up. There were no acute or late toxicities noted. For treatment to the knee, there were 4 (28.6%) recurrences, all in cases where there were pre-operative heterotopic ossification. There were two other recurrences in the non-hip, elbow or knee sites: one patient who received radiation therapy to the abdominal wall and one patient who underwent treatment to the thigh.<b> Conclusions</b>
  <b>: </b>
  Prophylactic radiation therapy with 700 cGy or 800 cGy in 1 fraction either before or after surgery remains a safe and effective treatment for both hip and most non-hip sites. Fractionated treatment may be used for larger treatment fields, however experience is limited.
 
</p></abstract><kwd-group><kwd>Heterotopic Ossification</kwd><kwd> Radiation Therapy</kwd><kwd> Knee</kwd><kwd> Elbow</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Heterotopic ossification (HO) is the development of bone in soft tissue. It can develop in various sites around the body, usually in a postoperative or post-traumatic setting near a joint space. Heterotopic ossification can affect quality of life with symptoms including pain, swelling, and loss of joint motion. Rates of HO formation vary by risk factors, including history of previous HO or fracture. Radiation therapy (RT) is well-established in high-risk patients for prevention of HO development for the hip [<xref ref-type="bibr" rid="scirp.81591-ref1">1</xref>] . There are multiple randomized controlled trials showing that 7 Gy in 1 fraction within 72 hours of surgery decreases the risk of development of HO in these patients [<xref ref-type="bibr" rid="scirp.81591-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref4">4</xref>] .</p><p>Prophylactic RT has been used in non-hip sites including the elbow and knee; however, this data is more limited [<xref ref-type="bibr" rid="scirp.81591-ref5">5</xref>] . O of the elbow can occur in up to 56% of patients with a radial head fracture [<xref ref-type="bibr" rid="scirp.81591-ref6">6</xref>] . For patients with a dislocation with an associated fracture, rates can be 5% - 20% [<xref ref-type="bibr" rid="scirp.81591-ref7">7</xref>] . Recurrence after excision has not been well documented. There is no standard recommendation for the role of RT prophylaxis for HO of the elbow.</p><p>Literature for HO of the knee is even less common. There are multiple case reports and a retrospective study with 12 patients [<xref ref-type="bibr" rid="scirp.81591-ref8">8</xref>] - [<xref ref-type="bibr" rid="scirp.81591-ref15">15</xref>] . The development of HO has been noted after total knee arthroplasty in up to approximately 40% of patients [<xref ref-type="bibr" rid="scirp.81591-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref12">12</xref>] . HO of the knee can also occur after dislocation, most notably after posterior cruciate ligament reconstruction [<xref ref-type="bibr" rid="scirp.81591-ref16">16</xref>] . The disease is typically characterized by bony formation near the quadriceps expansion and can result in pain or loss of mobility [<xref ref-type="bibr" rid="scirp.81591-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref15">15</xref>] . Prophylactic radiotherapy for the knee has not been well reported.</p><p>Overall, there is limited data for radiation prophylaxis outside of the hip. In this study, we report our institution’s experience with use of RT for prophylaxis of HO in non-hip sites.</p></sec><sec id="s2"><title>2. Methods</title><p>After obtaining IRB approval, a query was performed for patients with a diagnosis of heterotopic ossification treated with radiation therapy in our department. A review of electronic medical records including treatment records was performed. Our search found 255 patients who had either preoperative or postoperative prophylactic RT for HO at our institution from October 2004 to August 2015. Of those 255 patients, 218 received treatment to the hip, 15 to the elbow, 13 to the knee (1 bilateral for a total of 14 knees), and 10 to other sites (2 leg stump, 2 pubic symphysis, 1 femur, 1 foot, 1 humerus stump, 1 abdominal wall, 1 shoulder, 1 thigh). Patient data including demographics, radiation and surgery details, acute and chronic toxicities, and follow-up were collected on all patients. We report local failure and toxicity.</p><p>All patients were treated with linear accelerators using photons with anterior-posterior-posterio-anterior (AP-PA) beams.</p><p>Data analysis was conducted using JMP statistical software (SAS Institute Inc., Cary, North Carolina).</p></sec><sec id="s3"><title>3. Results</title><p>A total of 39 non-hip sites in 38 patients were treated with prophylactic RT for HO at our institution. A breakdown of sites is shown in <xref ref-type="table" rid="table1">Table 1</xref>. All but 1 patient were treated with a single fraction to 700 or 800 cGy. The exception was treated with 2000 cGy in 10 fractions to HO extending from the xiphoid process to the abdominal wall.</p><sec id="s3_1"><title>3.1. Elbow</title><p>Fifteen patients underwent treatment to the elbow with a median follow-up of 5 months (0 - 99). Median age for this group was 50 years (37 - 69). Nine (60.0%) patients had evidence of HO prior to surgery. Types of surgeries are listed in <xref ref-type="table" rid="table2">Table 2</xref>. Thirteen (86.7%) patients had RT postoperatively. Two patients (13.3%) had treatment preoperatively. All (100%) patients were free from recurrence at follow-up. There were no acute or late toxicities noted.</p></sec><sec id="s3_2"><title>3.2. Knee</title><p>Thirteen patients received treatment to a total of 14 knees (1 patient had bilateral knee treatment). The median follow-up was 21.5 months (1 - 110). Median age for this group was 66.5 years (21 - 81). Eight (61.5%) patients had evidence of preoperative HO. All knees were treated with postoperative RT receiving 700</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> A breakdown by anatomic site shows most common non-hip sites treated</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Anatomical Site</th><th align="center" valign="middle" >Number Treated</th></tr></thead><tr><td align="center" valign="middle" >Elbow</td><td align="center" valign="middle" >15</td></tr><tr><td align="center" valign="middle" >Knee</td><td align="center" valign="middle" >14</td></tr><tr><td align="center" valign="middle" >Femur/femur stump</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Non-hip joint pelvic bone</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Humerus stump</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Shoulder</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Abdomen</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Foot</td><td align="center" valign="middle" >1</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> A breakdown of surgeries shows the most common elbow surgery was elbow arthroplasty</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Surgery/Procedure</th><th align="center" valign="middle" >Number of Patients</th></tr></thead><tr><td align="center" valign="middle" >Elbow arthroplasty</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >Heterotopic debridement</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Open reduction and/or fixation</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Radial ulnar synostosis takedown</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Contracture release</td><td align="center" valign="middle" >1</td></tr></tbody></table></table-wrap><p>cGy in 1 fraction. There were 4 (28.6%) recurrences, all in cases where preoperative HO was noted. Two of the recurrences occurred in the same patient who had bilateral RT after bilateral knee manipulation. This patient had bilateral total knee arthroplasty 48 days prior to this knee manipulation and subsequent RT. She then underwent HO excision the following year. The recurrences are outlined in <xref ref-type="table" rid="table3">Table 3</xref>. There were no acute or late toxicities noted.</p></sec><sec id="s3_3"><title>3.3. Other Sites</title><p>There were 10 patients who received RT to non-hip, elbow, or knee sites. These sites are outlined in <xref ref-type="table" rid="table4">Table 4</xref>. There were 2 recurrences in this group: 1 patient received RT to the abdominal wall, and 1 underwent treatment to the thigh. The patient who received RT to the abdominal wall had myositis ossificans extending from the xiphoid process to the pubic symphysis. His disease developed after significant abdominal wall trauma. <xref ref-type="fig" rid="fig1">Figure 1</xref> shows this patient’s extent of disease. He received 2000 cGy in 10 fractions.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>Radiation therapy (RT) for prophylaxis of heterotopic ossification (HO) for the hip is well-established [<xref ref-type="bibr" rid="scirp.81591-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref4">4</xref>] . The same therapy for other sites is not as widely reported. In this article, we add to the growing body of literature for knee, elbow, and other sites that are at high-risk for developing HO.</p><p>In our study, patients who received RT to the elbow had no HO recurrences and no toxicities, demonstrating that this treatment is safe and effective. Other reports for RT to the elbow found similar results [<xref ref-type="bibr" rid="scirp.81591-ref17">17</xref>] . A study from Cleveland Clinic reported on 36 patients who underwent surgery and postoperative single-fraction RT [<xref ref-type="bibr" rid="scirp.81591-ref18">18</xref>] . They found that only 3 (8%) of the patients developed new HO after therapy. A study from Rush University in 2011 evaluated 44 patients who underwent RT after surgery to the elbow and had post-therapy radiographs [<xref ref-type="bibr" rid="scirp.81591-ref19">19</xref>] . They found at a follow-up of 136 days that 21 (48%) of the patients had developed HO.</p><p>We had similar outcomes with patients undergoing treatment to the knee. While 4 (28.6%) patients experienced recurrent disease, all of them had evidence of HO prior to surgery. One patient who had bilateral recurrence had knee</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Three patients had knee recurrences with time to progression ranging from 1 to 13 months</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Patient</th><th align="center" valign="middle" >Surgery/Procedure</th><th align="center" valign="middle" >Time to RT</th><th align="center" valign="middle" >Preoperative HO</th><th align="center" valign="middle" >Time to Recurrence/Progression</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Revision of total knee arthroplasty</td><td align="center" valign="middle" >1 day</td><td align="center" valign="middle" >Present</td><td align="center" valign="middle" >13 months</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Total knee arthroplasty</td><td align="center" valign="middle" >&lt;1 day</td><td align="center" valign="middle" >Present</td><td align="center" valign="middle" >1 month</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >Bilateral knee manipulation</td><td align="center" valign="middle" >2 days</td><td align="center" valign="middle" >Present (bilateral)</td><td align="center" valign="middle" >1 month</td></tr></tbody></table></table-wrap><p>HO: Heterotopic ossification; RT: Radiation therapy.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Other sites</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Site</th><th align="center" valign="middle" >Type of Surgery</th><th align="center" valign="middle" >Radiation Dose/Fraction</th><th align="center" valign="middle" >Recurrence?</th></tr></thead><tr><td align="center" valign="middle" >Iliac crest and pubic symphysis</td><td align="center" valign="middle" >HO excision</td><td align="center" valign="middle" >700 cGy/1 fx</td><td align="center" valign="middle" >No</td></tr><tr><td align="center" valign="middle" >Superior pubic ramus and obturator foramen</td><td align="center" valign="middle" >HO excision</td><td align="center" valign="middle" >700 cGy/ 1 fx</td><td align="center" valign="middle" >No</td></tr><tr><td align="center" valign="middle" >Femur</td><td align="center" valign="middle" >HO excision</td><td align="center" valign="middle" >700 cGy/1 fx</td><td align="center" valign="middle" >No</td></tr><tr><td align="center" valign="middle" >Femur</td><td align="center" valign="middle" >HO excision</td><td align="center" valign="middle" >700 cGy/1 fx</td><td align="center" valign="middle" >Yes</td></tr><tr><td align="center" valign="middle" >Femur stump</td><td align="center" valign="middle" >Above-the-knee amputation</td><td align="center" valign="middle" >700 cGy/1 fx</td><td align="center" valign="middle" >No</td></tr><tr><td align="center" valign="middle" >Femur stump</td><td align="center" valign="middle" >Above-the-knee amputation</td><td align="center" valign="middle" >700 cGy/1 fx</td><td align="center" valign="middle" >No</td></tr><tr><td align="center" valign="middle" >Foot</td><td align="center" valign="middle" >HO excision</td><td align="center" valign="middle" >700 cGy/1 fx</td><td align="center" valign="middle" >No</td></tr><tr><td align="center" valign="middle" >Abdomen</td><td align="center" valign="middle" >HO excision</td><td align="center" valign="middle" >2000 cGy/10 fx</td><td align="center" valign="middle" >Yes</td></tr><tr><td align="center" valign="middle" >Humerus stump</td><td align="center" valign="middle" >Above-the-elbow amputation, HO excision</td><td align="center" valign="middle" >700 cGy/1 fx</td><td align="center" valign="middle" >No</td></tr><tr><td align="center" valign="middle" >Shoulder</td><td align="center" valign="middle" >HO excision</td><td align="center" valign="middle" >700 cGy/1 fx</td><td align="center" valign="middle" >No</td></tr></tbody></table></table-wrap><p>HO: Heterotopic ossification.</p><p>manipulation and RT 48 days after an initial bilateral arthroplasty. There was no report of HO excision at the time of knee manipulation prior to RT. This leads to the question of whether or not the timing of RT this late after bilateral arthroplasty contributed to this patient having recurrence and progression of disease. Overall, there were no toxicities, acute or late, noted.</p><p>One report from Drexel University with 12 patients who underwent RT for knee HO prophylaxis had no HO recurrence after treatment [<xref ref-type="bibr" rid="scirp.81591-ref8">8</xref>] . This patient group differed from ours as 8 (61.5%) of our patients versus none of their patients had evidence of HO prior to surgery. A report by Chidel et al. detailed their experience with 5 patients who received knee HO prophylaxis with RT [<xref ref-type="bibr" rid="scirp.81591-ref13">13</xref>] . They had no progression or recurrence of HO, reporting that the treatment was well tolerated.</p><p>Although acute side effects are minimal, the risk for secondary malignancy is always an important concern in the treatment of benign disorders. There have been case reports for developing soft tissue sarcomas within the field of single-fraction RT for HO [<xref ref-type="bibr" rid="scirp.81591-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.81591-ref21">21</xref>] . However, none of the larger series of both hip and non-hip sites have shown any evidence of the development of secondary malignancy within the treatment field. A study by Berris et al. outlined peripheral organ doses from radiotherapy for non-hip sites [<xref ref-type="bibr" rid="scirp.81591-ref22">22</xref>] . They found for shoulder, elbow, and knee treatments that equivalent peripheral organ doses were 0.85 - 62 mSv, 0.28 - 1.6 mSv, and 0.04 - 1.6 mSv, respectively. This corresponded to cancer risks of 0 - 5.1, 0 - 0.6, and 0 - 1.3 cases per 10,000 persons. The highest risks were with treatment to the shoulder in developing malignancies of skin (5.1 cases per 10,000) and breast (3.8 cases per 10,000). Though the risk for secondary malignancy remains, it is evidently extremely rare, especially in elbow and knee treatments.</p><p>A noted obvious limitation of this study is its retrospective nature and heterogeneous patient cohort.</p></sec><sec id="s5"><title>5. Conclusion</title><p>RT prophylaxis with 700 cGy in 1 fraction either before or after surgery remains a safe and effective treatment for both hip and most non-hip sites.</p></sec><sec id="s6"><title>Cite this paper</title><p>Patel, A.B., Tzou, K.S., Single, M., Hollant, L., Smart, B., Gaines, K., Sherman, C.E., Peterson, J.L., Ko, S.J., Vallow, L.A., Miller, R.C. and Buskirk, S.J. (2018) Radiation Therapy Prophylaxis for Heterotopic Ossification in Non-Hip Sites. Journal of Cancer Therapy, 9, 1-8. https://doi.org/10.4236/jct.2018.91001</p></sec></body><back><ref-list><title>References</title><ref id="scirp.81591-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Pakos, E.E. and Ioannidis, J.P. (2004) Radiotherapy vs. Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Heterotopic Ossification after Major Hip Procedures: A Meta-Analysis of Randomized Trials. International Journal of Radiation Oncology, Biology, Physics, 60, 888-895. https://doi.org/10.1016/j.ijrobp.2003.11.015</mixed-citation></ref><ref id="scirp.81591-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Seegenschmiedt, M.H., Keilholz, L., Martus, P., et al. (1997) Prevention of Heterotopic Ossification about the Hip: Final Results of Two Randomized Trials in 410 Patients Using either Preoperative or Postoperative Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics, 39, 161-171.  
https://doi.org/10.1016/S0360-3016(97)00285-X</mixed-citation></ref><ref id="scirp.81591-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kolbl, O., Knelles, D., Barthel, T., Raunecker, F., Flentje, M. and Eulert, J. (1998) Preoperative Irradiation versus the Use of Nonsteroidal Anti-Inflammatory Drugs for Prevention of Heterotopic Ossification Following Total Hip Replacement: The Results of a Randomized Trial. International Journal of Radiation Oncology, Biology, Physics, 42, 397-401. https://doi.org/10.1016/S0360-3016(98)00204-1</mixed-citation></ref><ref id="scirp.81591-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Seegenschmiedt, M.H., Makoski, H.B. and Micke, O. (2001) Radiation Prophylaxis for Heterotopic Ossification about the Hip Joint—A Multicenter Study. International Journal of Radiation Oncology, Biology, Physics, 51, 756-765.  
https://doi.org/10.1016/S0360-3016(01)01640-6</mixed-citation></ref><ref id="scirp.81591-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Mishra, M.V., Austin, L., Parvizi, J., Ramsey, M. and Showalter, T.N. (2011) Safety and Efficacy of Radiation Therapy as Secondary Prophylaxis for Heterotopic Ossification of Non-Hip Joints. Journal of Medical Imaging and Radiation Oncology, 55, 333-336. https://doi.org/10.1111/j.1754-9485.2011.02275.x</mixed-citation></ref><ref id="scirp.81591-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ilahi, O.A., Strausser, D.W. and Gabel, G.T. (1998) Post-Traumatic Heterotopic Ossification about the Elbow. Orthopedics, 21, 265-268.</mixed-citation></ref><ref id="scirp.81591-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Thompson 3rd, H.C. and Garcia, A. (1967) Myositis Ossificans: Aftermath of Elbow Injuries. Clinical Orthopaedics and Related Research, 50, 129-134.  
https://doi.org/10.1097/00003086-196701000-00012</mixed-citation></ref><ref id="scirp.81591-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Daugherty, L.C., Bell, J.R., Fisher, B.J., et al. (2013) Radiation Prophylaxis as Primary Prevention of Heterotopic Ossification of the Knee: Classification of Disease and Indications for Treatment. International Journal of Radiation Oncology, 2, 87-94.  
https://doi.org/10.1007/s13566-012-0077-0</mixed-citation></ref><ref id="scirp.81591-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Rader, C.P., Barthel, T., Haase, M., Scheidler, M. and Eulert, J. (1997) Heterotopic Ossification after Total Knee Arthroplasty. 54/615 Cases After 1-6 Years’ Follow-Up. Acta Orthopaedica Scandinavica, 68, 46-50.  
https://doi.org/10.3109/17453679709003974</mixed-citation></ref><ref id="scirp.81591-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Toyoda, T., Matsumoto, H., Tsuji, T., Kinouchi, J. and Fujikaw, K. (2003) Heterotopic Ossification after Total Knee Arthroplasty. Journal of Arthroplasty, 18, 760-764.  
https://doi.org/10.1016/S0883-5403(03)00194-3</mixed-citation></ref><ref id="scirp.81591-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Dalury, D.F. and Jiranek, W.A. (2004) The Incidence of Heterotopic Ossification after Total Knee Arthroplasty. Journal of Arthroplasty, 19, 447-452.  
https://doi.org/10.1016/j.arth.2003.12.064</mixed-citation></ref><ref id="scirp.81591-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Furia, J.P. and Pellegrini Jr., V.D. (1995) Heterotopic Ossification Following Primary Total Knee Arthroplasty. Journal of Arthroplasty, 10, 413-419.  
https://doi.org/10.1016/S0883-5403(05)80139-1</mixed-citation></ref><ref id="scirp.81591-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chidel, M.A., Suh, J.H. and Matejczyk, M.B. (2001) Radiation Prophylaxis for Heterotopic Ossification of the Knee. Journal of Arthroplasty, 16, 1-6.  
https://doi.org/10.1054/arth.2001.16492</mixed-citation></ref><ref id="scirp.81591-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Harwin, S.F., Stein, A.J., Stern, R.E. and Kulick, R.G. (1993) Heterotopic Ossification following Primary Total Knee Arthroplasty. Journal of Arthroplasty, 8, 113-116.  
https://doi.org/10.1016/S0883-5403(06)80048-3</mixed-citation></ref><ref id="scirp.81591-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Chan, P.K., Chiu, K.Y., Ng, F.Y. and Yan, C.H. (2014) Bony Ankylosis of the Knee Secondary to Heterotopic Ossification after Total Knee Arthroplasty: A Case Report. Journal of Orthopaedic Surgery (Hong Kong), 22, 434-436.  
https://doi.org/10.1177/230949901402200334</mixed-citation></ref><ref id="scirp.81591-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Whelan, D.B., Dold, A.P., Trajkovski, T. and Chahal, J. (2014) Risk Factors for the Development of Heterotopic Ossification after Knee Dislocation. Clinical Orthopaedics and Related Research, 472, 2698-2704.  
https://doi.org/10.1007/s11999-014-3730-7</mixed-citation></ref><ref id="scirp.81591-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Stein, D.A., Patel, R., Egol, K.A., Kaplan, F.T., Tejwani, N.C. and Koval, K.J. (2003) Prevention of Heterotopic Ossification at the Elbow Following Trauma Using Radiation Therapy. Bulletin (Hospital for Joint Diseases), 61, 151-154.</mixed-citation></ref><ref id="scirp.81591-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Robinson, C.G., Polster, J.M., Reddy, C.A., et al. (2010) Postoperative Single-Fraction Radiation for Prevention of Heterotopic Ossification of the Elbow. International Journal of Radiation Oncology, Biology, Physics, 77, 1493-1499.  
https://doi.org/10.1016/j.ijrobp.2009.06.072</mixed-citation></ref><ref id="scirp.81591-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Strauss, J.B., Wysocki, R.W., Shah, A., et al. (2011) Radiation Therapy for Heterotopic Ossification Prophylaxis after High-Risk Elbow Surgery. American Journal of Orthopedics, 40, 400-405.</mixed-citation></ref><ref id="scirp.81591-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Mourad, W.F., Packianathan, S., Shourbaji, R.A., Russell, G., Khan, M.A. and Vijayakumar, S. (2012) Radiation-Induced Sarcoma Following Radiation Prophylaxis of Heterotopic Ossification. Practical Radiation Oncology, 2, 151-154.  
https://doi.org/10.1016/j.prro.2011.06.005</mixed-citation></ref><ref id="scirp.81591-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Farris, M.K., Chowdhry, V.K., Lemke, S., Kilpatrick, M. and Lacombe, M. (2012) Osteosarcoma Following Single Fraction Radiation Prophylaxis for Heterotopic Ossification. Radiation Oncology, 7, 140. https://doi.org/10.1186/1748-717X-7-140</mixed-citation></ref><ref id="scirp.81591-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Berris, T., Mazonakis, M., Kachris, S. and Damilakis, J. (2014) Peripheral Organ Doses from Radiotherapy for Heterotopic Ossification of Non-Hip Joints: Is There a Risk for Radiation-Induced Malignancies? Physics in Medicine, 30, 309-313.  
https://doi.org/10.1016/j.ejmp.2013.09.003</mixed-citation></ref></ref-list></back></article>